G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at
Preliminary data from three additional randomized Phase 2 clinical trials of trilaciclib expected by end of 2018
Management to host webcast and conference call today at
“Data from our randomized Phase 2 clinical trial of trilaciclib and chemotherapy in first-line small cell lung cancer showed robust myelopreservation benefits. By the end of the year, we will report data from three additional randomized Phase 2 trials in a variety of indications. Collectively these trials will provide preliminary data on the potential anti-tumor efficacy and myelopreservation benefits of trilaciclib across different indications, lines of therapy, and chemotherapy regimens,” said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. “We plan to request meetings with U.S. and European regulatory authorities in early 2019 to discuss data from more than three hundred participants who received trilaciclib across multiple clinical trials.”
“Enrollment remains on track for our lerociclib clinical trials in ER+, HER2- breast cancer and EGFRm non-small cell lung cancer, as well as our G1T48 trial in ER+, HER2- breast cancer, and we plan to report data on each of these programs in 2019,” said
- Presented additional data from randomized Phase 2 trial of trilaciclib in combination with etoposide/carboplatin for treatment of first-line small cell lung cancer (SCLC): In October, new data analyses presented at the European Society for Medical Oncology (
ESMO) 2018 Congress demonstrated improvements in neutrophil, red blood cell and lymphocyte measures in patients treated with trilaciclib compared to placebo. With regard to lymphocytes, trilaciclib preserved or improved B cell and T cell subset counts, including activated CD8+ cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios in peripheral blood compared to placebo. The poster titled “Trilaciclib preserves and enhances immune system function in extensive-stage small cell lung cancer (SCLC) patients receiving first-line chemotherapy” was recognized as a “Best Poster” at ESMO.
- Expediting analyses of myelopreservation data from the randomized Phase 2 trial of trilaciclib/chemotherapy/Tecentriq® (atezolizumab) in SCLC; data to be reported by year end 2018: As disclosed on
September 17, the company elected to make myelopreservation the primary outcome measure and overall survival a secondary outcome measure of the trilaciclib/chemotherapy/Tecentriq trial in first-line SCLC. This protocol amendment was made to provide earlier access to myelopreservation data that has the potential to confirm the myelopreservation results observed in the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy. Both trials evaluated trilaciclib in first-line SCLC using the same chemotherapy backbone of etoposide and carboplatin.
Garry Nicholsonto the board of directors: Mr. Nicholson previously led the global oncology franchise at Pfizer in the role of President, Pfizer Oncology. During his tenure, he oversaw the development and commercialization of the CDK4/6 inhibitor Ibrance® (palbociclib). Mr. Nicholson currently serves on the boards of directors of Five Prime Therapeutics, Inc., TESARO, Inc., and SQZ Biotechnologies.
Anticipated Milestones for Fourth Quarter 2018
- Report preliminary data from the randomized Phase 2 clinical trial of trilaciclib/chemotherapy/Tecentriq in first-line SCLC.
- Report preliminary data from the randomized Phase 2 clinical trial of trilaciclib/chemotherapy in second-/third-line SCLC.
- Present preliminary data from the randomized Phase 2 clinical trial of trilaciclib/chemotherapy in metastatic triple-negative breast cancer (mTNBC) in a poster discussion Spotlight Session at the San Antonio Breast Cancer Symposium on
December 5, 2018.
- Present preclinical data on trilaciclib/chemotherapy combinations in CDK4/6-dependent tumor models at the 30th EORTC-NCI-AACR Symposium on
November 13, 2018.
- Complete enrollment of the Phase 2a trial of lerociclib/Faslodex® (fulvestrant) in ER+, HER2- breast cancer.
Third Quarter 2018 Financial Highlights
- Completed offering of common stock: The company completed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $60.00 per share, including 450,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in September. G1 received approximately $194.9 million in proceeds from the offering, net of underwriting discounts and commissions and other offering expenses payable by G1.
- Cash Position: Cash, cash equivalents and short-term investments totaled
$390.5 millionas of September 30, 2018, compared to $103.8 millionas of December 31, 2017. This increase results from the receipt of $107.9 millionin net proceeds from a secondary offering in March, $36.1 millionin net proceeds from “at the market offerings” between June 18 and August 2, 2018, and $194.9 millionin net proceeds from a follow-on offering in September, partially offset by $53.1 millionof cash used for operating activities.
- Operating Expenses: Operating expenses were
$20.8 millionfor the third quarter of 2018, compared to $15.9 millionfor the third quarter of 2017. GAAP operating expenses include stock-based compensation expense of $3.3 millionfor the third quarter of 2018, compared to $1.0 millionfor the third quarter of 2017.
- Research and Development Expenses: Research and development (R&D) expenses for the third quarter of 2018 were
$15.9 million, compared to $14.1 millionfor the third quarter of 2017. The increase in expense was due to an increase of $3.6 millionin clinical program costs, offset by a decrease of $1.0 millionin drug manufacturing costs and a decrease of $0.8 millionin preclinical expenses.
- General and Administrative Expenses: General and administrative (G&A) expenses for the third quarter of 2018 were
$4.9 million, compared to $1.9 millionfor the third quarter of 2017. The increase in expense was largely driven by personnel-related costs due to an increase in headcount and non-cash stock compensation expense charges.
- Net Loss: G1 reported a net loss of
$19.9 millionfor the third quarter of 2018, compared to $15.6 millionfor the third quarter of 2017.
Webcast and Conference Call
The management team will host a webcast and conference call at
G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, lerociclib and G1T48, and are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the Company’s ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the Company’s initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; the Company’s development of a CDK4/6 inhibitor to reduce chemotherapy-induced myelosuppression is novel, unproven and rapidly evolving and may never lead to a marketable product; and market conditions. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Head of Investor and Public Relations
|G1 Therapeutics, Inc.|
|Balance Sheet Data|
|September 30,||December 31,|
|Cash and cash equivalents||$||390,524||$||103,812|
|Total stockholders’ equity||$||379,255||$||93,388|
|G1 Therapeutics, Inc.|
|Condensed Statements of Operations|
|(in thousands, except per share data)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development||15,873||14,054||51,605||38,806|
|General and administrative||4,949||1,875||11,595||4,881|
|Total operating expenses||20,822||15,929||63,200||43,687|
|Other income (expense)|
|Change in fair value in warrant liability and other liabilities||—||—||-||(41||)|
|Total other income, net||904||328||2,003||547|
|Accretion of redeemable convertible preferred stock||—||—||-||(4,757||)|
|Net loss attributable to common stockholders||$||(19,918||)||$||(15,601||)||$||(61,197||)||$||(47,897||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.59||)||$||(0.55||)||$||(1.91||)||$||(3.24||)|
|Weighted average common shares outstanding, basic and diluted||33,829,437||28,318,656||32,006,978||14,772,621|
Source: G1 Therapeutics